Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Stroke. 2021 May 4;52(7):2414–2417. doi: 10.1161/STROKEAHA.121.034089

Table 2.

Event rates and Cox models showing hazard ratios for the clopidogreal treatment arm, stratified by carotid stenosis <50% versus ≥ 50%, and a model with the interaction term of stenosis*treatment.

Stratification Placebo
event rate
(n, %)		 Clopidogrel
event rate
(n, %)		 Unadjusted
hazard ratio
(95% CI)		 p value Adjusted
hazard ratio*
(95% CI)		 p value
Stenosis <50%
(n=3,665)		 105/1835, 5.7% 73/1830, 4.0% 0.69
(0.51-0.93)		 0.014 0.68
(0.50-0.93)		 0.014
Stenosis ≥50%
(n=276)		 19/137, 13.9% 17/139, 12.2% 0.86
(0.45-1.65)		 0.650 0.88
(0.45-1.72)		 0.703
Interaction of stenosis*treatment 0.573
*

Adjusted for age, sex, race, ethnicity, qualifying event (stroke vs transient ischemic attack), smoking status, diabetes, hypertension, coronary artery disease, and statin use.